Novo Nordisk
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after the company report...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market prese...
Latest News
12 hours ago · zacks.com
NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSemaNovo secures EC approval for Frehemgo while CagriSema delivers up to 21% weight loss, adding momentum to its turnaround efforts amid intensifying obesity drug competition.
17 hours ago · wsj.com
Novo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug ApprovalThe Danish drugmaker released encouraging results from studies and European regulators approved a hemophilia treatment, pushing the stock higher premarket.
2 days ago · reuters.com
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data showNovo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
4 days ago · 247wallst.com
Blackstone Is Paying Up to $1.5 Billion for Pfizer’s Answer to WegovyPfizer just convinced Wall Street's biggest private investor to shoulder its obesity bet, yet the payoff for shareholders may not come from the drug at all. The real story sits in who keeps the upside and what arrives first.
4 days ago · prnewswire.com
Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine/PRNewswire/ -- Novo Nordisk today announced a partnership with DJ Khaled for Wegovy (semaglutide). The partnership is personal for Khaled, who has been
4 days ago · seekingalpha.com
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For November 2026The 4-Factor Dividend Growth Strategy targets quality and total return, outperforming SCHD with a 14.98% average return versus SCHD's 14.31%. I select stocks based on free cash flow to debt, 5-year dividend growth, return on capital employed, and forward yield, emphasizing growth and quality. Recent SCHD outperformance has narrowed the gap, but my strategy has regained momentum since September 2026.
4 days ago · seekingalpha.com
Novo Nordisk: Better Than It Looks, But Not A Buy YetI maintain my Hold rating on Novo Nordisk, but have become more optimistic about its longer-term prospects, particularly due to its broader pipeline and franchise strategy. Q3 revenue growth was driven almost entirely by the Wegovy pill; excluding it, group revenues would have declined by approximately 2%. Pricing pressure remains significant, with net price declines of 10–15% for Ozempic and 30–35% for Wegovy, and further risk from patent expiries.
5 days ago · fool.com
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?JPMorgan Chase was expecting Novo Nordisk to report strong Wegovy pill sales, and it did. The company's GLP-1 pill sales support the volume-driven business plan, but it is still in a transition phase.
5 days ago · seekingalpha.com
Novo Nordisk: Valuations Are Blind To The UpsideNovo Nordisk A/S had a broad beat in Q3 2026, with revenue and operating profit having less accounting noise. Successive NVO guidance upgrades seem to have been largely overlooked. Gross-to-net rebate adjustments are being underestimated amidst conservative guidance.
6 days ago · 247wallst.com
Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds SteadyA surprise quarterly loss and a weaker profit outlook are hitting Hims & Hers (NYSE:HIMS) hard. Hims & Hers stock was last at $18.77, down 18%.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove NVO